Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DYN Dyne Therapeutics	$6.91 -7.8%	$12.69	$6.86 ▼ $47.45	$781.44M	1.21	2.23 million shs	1.25 million shs
INDV Indivior	$9.15 -2.6%	$9.93	$7.33 ▼ $21.64	$1.26B	0.93	914,377 shs	462,530 shs
TECX Tectonic Therapeutic	$14.93 -3.9%	$27.74	$14.69 ▼ $61.07	$280.04M	2.87	169,585 shs	222,206 shs
WVE Wave Life Sciences	$5.66 -2.4%	$10.17	$4.25 ▼ $16.74	$870.27M	-0.93	1.16 million shs	932,948 shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DYN Dyne Therapeutics	-9.54%	-28.39%	-39.60%	-68.60%	-71.67%
INDV Indivior	+2.62%	-1.47%	-3.20%	-24.27%	-56.51%
TECX Tectonic Therapeutic	-0.58%	-12.31%	-33.00%	-66.65%	+1,552,999,900.00%
WVE Wave Life Sciences	-3.81%	-28.22%	-38.30%	-55.66%	-1.86%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DYN Dyne Therapeutics	3.1679 of 5 stars	4.5	1.0	0.0	3.2	4.2	0.0
INDV Indivior	3.2583 of 5 stars	3.6	3.0	0.0	3.0	1.7	1.9
TECX Tectonic Therapeutic	3.1227 of 5 stars	3.6	4.0	0.0	2.4	3.3	0.6
WVE Wave Life Sciences	4.4813 of 5 stars	3.5	3.0	4.8	3.3	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DYN Dyne Therapeutics	3.07	Buy	$47.46	533.67% Upside
INDV Indivior	3.25	Buy	$15.00	59.74% Upside
TECX Tectonic Therapeutic	3.17	Buy	$77.75	400.64% Upside
WVE Wave Life Sciences	3.00	Buy	$22.60	289.66% Upside

Current Analyst Ratings Breakdown

Latest TECX, INDV, DYN, and WVE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/26/2025	WVE Wave Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
3/21/2025	DYN Dyne Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$18.00 ➝ $17.00
3/21/2025	TECX Tectonic Therapeutic	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$112.00 ➝ $101.00
3/17/2025	DYN Dyne Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
3/17/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
3/12/2025	DYN Dyne Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$50.00
3/7/2025	DYN Dyne Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$50.00
3/6/2025	INDV Indivior	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $13.00
3/5/2025	WVE Wave Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
2/28/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
2/28/2025	DYN Dyne Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$53.00 ➝ $48.00

(Data available from 4/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$1.49 per share	N/A
INDV Indivior	$1.19B	1.09	$1.90 per share	4.94	N/A	∞
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	$2.13 per share	N/A
WVE Wave Life Sciences	$108.30M	8.22	N/A	N/A	$0.40 per share	14.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DYN Dyne Therapeutics	-$235.94M	-$3.35	N/A	N/A	N/A	N/A	-57.46%	-51.62%	5/1/2025 (Estimated)
INDV Indivior	$2M	-$0.35	N/A	5.49	N/A	-3.96%	-241.73%	15.09%	4/24/2025 (Estimated)
TECX Tectonic Therapeutic	$12.16M	-$6.53	N/A	N/A	N/A	N/A	-35.53%	-31.97%	5/8/2025 (Estimated)
WVE Wave Life Sciences	-$57.51M	-$0.79	N/A	N/A	N/A	-66.50%	-280.57%	-52.90%	5/8/2025 (Estimated)

Latest TECX, INDV, DYN, and WVE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	N/A	DYN Dyne Therapeutics	-$0.88	N/A	N/A	N/A	N/A	N/A
4/24/2025	N/A	INDV Indivior	$0.22	N/A	N/A	N/A	$240.13 million	N/A
3/20/2025	Q4 2024	TECX Tectonic Therapeutic	-$1.39	-$0.84	+$0.55	-$0.84	N/A	N/A
3/4/2025	Q4 2024	DYN Dyne Therapeutics	-$0.92	-$0.88	+$0.04	-$0.88	N/A	N/A
3/4/2025	Q4 2024	WVE Wave Life Sciences	-$0.17	$0.17	+$0.34	$0.17	$25.60 million	$83.75 million
2/20/2025	Q4 2024	INDV Indivior	$0.32	$0.32	N/A	$0.07	$262.35 million	$298.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	N/A
WVE Wave Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DYN Dyne Therapeutics	N/A	17.02	17.02
INDV Indivior	N/A	0.83	0.65
TECX Tectonic Therapeutic	N/A	9.39	9.39
WVE Wave Life Sciences	N/A	1.90	1.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DYN Dyne Therapeutics	96.68%
INDV Indivior	60.33%
TECX Tectonic Therapeutic	62.63%
WVE Wave Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
DYN Dyne Therapeutics	20.77%
INDV Indivior	N/A
TECX Tectonic Therapeutic	9.20%
WVE Wave Life Sciences	29.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DYN Dyne Therapeutics	100	113.12 million	80.63 million	Optionable
INDV Indivior	1,164	137.88 million	N/A	Not Optionable
TECX Tectonic Therapeutic	120	18.66 million	13.40 million	N/A
WVE Wave Life Sciences	240	153.49 million	108.14 million	Optionable

TECX, INDV, DYN, and WVE Headlines

Recent News About These Companies

Trexquant Investment LP Has $5.44 Million Stock Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE)

April 7 at 4:37 AM | marketbeat.com

Cinctive Capital Management LP Lowers Position in Wave Life Sciences Ltd. (NASDAQ:WVE)

April 5 at 5:47 AM | marketbeat.com

Wave Life Sciences (NASDAQ:WVE) Trading Down 2.8% - What's Next?

April 4, 2025 | marketbeat.com

Wave Life Sciences (NASDAQ:WVE) Shares Gap Down - What's Next?

April 3, 2025 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE) and Nuvation Bio (NUVB)

April 2, 2025 | markets.businessinsider.com

Wave’s Duchenne Therapy Has Promising Phase 2 Results

April 2, 2025 | managedhealthcareexecutive.com

Q1 Earnings Forecast for WVE Issued By Leerink Partnrs

April 1, 2025 | americanbankingnews.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Receives $22.60 Average Price Target from Analysts

March 31, 2025 | americanbankingnews.com

What is Leerink Partnrs' Estimate for WVE Q1 Earnings?

March 31, 2025 | marketbeat.com

Loomis Sayles & Co. L P Takes $20.55 Million Position in Wave Life Sciences Ltd. (NASDAQ:WVE)

March 30, 2025 | marketbeat.com

Artisan Partners Limited Partnership Trims Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE)

March 30, 2025 | marketbeat.com

Promising Genomics & Synthetic Biology Stocks to Consider in 2025

March 28, 2025 | zacks.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Position Increased by Swiss National Bank

March 28, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Buy" from Analysts

March 28, 2025 | marketbeat.com

WVE-N531 Shows Functional Benefits, Muscle Damage Reversal in DMD

March 27, 2025 | ajmc.com

Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531

March 27, 2025 | seekingalpha.com

Wave Life releases positive Phase II results for WVE-N531 in DMD

March 27, 2025 | thepharmaletter.com

Wave Life Sciences unveils Phase II data for DMD therapy, WVE-N531

March 27, 2025 | finance.yahoo.com

HC Wainwright Reaffirms Buy Rating for Wave Life Sciences (NASDAQ:WVE)

March 27, 2025 | marketbeat.com

Wave Life Sciences (NASDAQ:WVE) Shares Gap Up - Here's Why

March 27, 2025 | marketbeat.com

Wave to submit Duchenne drug for approval after Phase 2 success

March 27, 2025 | statnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
By Jeffrey Neal Johnson | March 21, 2025
View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
By Thomas Hughes | March 12, 2025
View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
3 Defense Stocks Set to Benefit From Increased Military Spending
By Chris Markoch | March 20, 2025
View 3 Defense Stocks Set to Benefit From Increased Military Spending
3 Companies Buying Back Stock—Why It Matters
By Gabriel Osorio-Mazilli | March 12, 2025
View 3 Companies Buying Back Stock—Why It Matters
New Tariffs May Bring Liberation to These 3 Steel Stocks
By Gabriel Osorio-Mazilli | April 7, 2025
View New Tariffs May Bring Liberation to These 3 Steel Stocks

TECX, INDV, DYN, and WVE Company Descriptions

Dyne Therapeutics NASDAQ:DYN

$6.91 -0.58 (-7.77%)

As of 02:43 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Indivior NASDAQ:INDV

$9.15 -0.24 (-2.56%)

As of 02:43 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Tectonic Therapeutic NASDAQ:TECX

$14.93 -0.60 (-3.86%)

As of 02:42 PM Eastern

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

Wave Life Sciences NASDAQ:WVE

$5.66 -0.14 (-2.41%)

As of 02:43 PM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time